Capstan Medical’s Robotic-Assisted TMVR Platform Successfully Used in FIH Procedures

March 6, 2025—Capstan Medical announced the successful completion of the first-in-human robotic-assisted transcatheter mitral valve replacement procedures with the company’s minimally invasive robotic structural heart platform.

According to Capstan, the procedures were performed on two patients at Hospital Clínico Universidad Católica in Santiago, Chile, by Gonzalo Martinez, MD, along with Santiago Garcia, MD, who supported the cases. Dr. Martinez is Director, Endovascular Therapy Center at the Pontifical Catholic University of Chile in Santiago. Dr. Garcia is Director, Structural Heart Program at The Christ Hospital in Cincinnati, Ohio.

“We are honored to pioneer this innovation that has the potential to transform how we treat heart valve disease, especially for patients who aren’t candidates for conventional surgery,” commented Dr. Martinez in the company’s press release. “The Capstan technology exceeded our expectations even in these early cases.

“These successful first-in-human cases represent a significant leap forward in structural heart intervention. I’ve worked with numerous technologies, but this fundamentally changes what’s possible in the treatment of valvular heart disease. The robotic platform provided unprecedented catheter stability and control, achieving optimal implant positioning. Both patients had elimination of their mitral regurgitation, with unobstructed left ventricular outflow tracts, and are feeling much better than how they arrived. This is the enabling technology the structural heart field has been waiting for.”

Capstan advised that after closing the $110 million Series C funding, which was announced in December 2024, it will continue the clinical and developmental work leading to pivotal trials. The company is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform, noted the press release.